Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Christopher J. Forlenza, MD, Nitya Gulati, MBBS, Audrey Mauguen, PhD, Michael J. Absalon, Sharon M. Castellino, MD MSc, Anna Franklin, MD, Frank G. Keller, MD, Neal Shukla, MD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-139480

Published: 2020

Journal Articles

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

Qi Wang, Todd M. Cooper, DO, Michael J. Absalon, E. Anders Kolb, MD, Grygoriy Vasilinin, Nathalie H. Gosselin, Todd A. Alonzo, PhD, J.F. Marier

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137163

Published: 2020

Journal Articles

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Qi Wang, Nathalie H. Gosselin, Michael J. Absalon, E. Anders Kolb, MD, J.F. Marier, Todd A. Alonzo, PhD, Stefan Faderl, Todd M. Cooper, DO

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137205

Published: 2020

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Michael J. Absalon, MD PhD, Erin H. Breese, MD PhD, Lynn Lee, MD, Maureen M O'Brien, MD MS, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, MD, Qi An, Jennifer Mangino, MD, Joel Kaplan, DO, Robin Norris, MD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 336.

https://doi.org/10.1182/blood-2018-99-119618

Published: 2018

Journal Articles

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

LaQuita M Jones, DO, Maureen M O'Brien, MD, Erin H. Breese, MD PhD, Karen Burns, MD, Jennifer Mangino, MD, Michael J. Absalon, MD PhD, Javier A. El-Bietar, MD, Michael Grimley, MD, Benjamin Mizukawa, MD, Lynn Lee, MD, John Peter Perentesis, MD, Christine L Phillips, MD

Blood (2017) 130 (Supplement 1): 3895.

https://doi.org/10.1182/blood.V130.Suppl_1.3895.3895

Published: 2017

Journal Articles

Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia

Richard McMasters, MD, Brian K. Turpin, DO, Michael J. Absalon, MD, PhD, Christine L. Phillips, MD, Karen Burns, MD, Christopher E. Dandoy, MD, Nihal Bakeer, MBBS, Jun Mo, MD, John Perentesis, MD, Maureen M. O'Brien, MD

Blood (2013) 122 (21): 4940.

https://doi.org/10.1182/blood.V122.21.4940.4940

Published: 2013

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Christine L Phillips, MD, Stella M. Davies, MBBS, PhD, Richard McMasters, MD, Maureen O'Brien, MD, MS, Michael J. Absalon, MD, PhD, Jeffrey A. Moscow, MD, Teresa Smolarek, PhD, John P. Perentesis, MD

Blood (2010) 116 (21): 1070.

https://doi.org/10.1182/blood.V116.21.1070.1070

Published: 2010

NARROW

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only